Results

Total Results: 2,146 records

Showing results for "factor".

41. Untitled (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/thromboembolism-update_research-protocol.pdf
    February 17, 2016 - There were few studies evaluating the new factor Xa inhibitors. … or treatment durations of the same thromboprophylaxis interventions (low molecular weight heparin, factor … All KQ o   Injectable unfractionated heparin KQ 1, 4 (in combination), 5, 6 o   Injectable or oral factor …  for  postthrombotic   syndrome  and  proximal  DVTs  are  believed  to  be  a  higher  risk  factor … 1) comparisons of classes of thromboprophylaxis interventions (e.g., low molecular weight heparin, factor

42. Effective Health Care Program
    effectivehealthcare.ahrq.gov/health-topics/c%C3%A1ncer-0
    December 08, 2017 - subchapter, 2006-2009 Research Report August 26, 2011 Data Points #15: Prognostic factor

43. 04-E029-1 Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_executive.pdf
    December 01, 2011 - Behavioral indications No cohort used this factor. … Gleason score No cohort used this factor. … Behavioral indications No cohort explicitly used this factor. … Availability of technology No study addressed this factor. … Small area variation No study addressed this factor.

44. Data Points 15: Breast Cancer Diagnostic Workup: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-prognostic-tests_research.pdf
    August 22, 2012 - Data Points 15: Breast Cancer Diagnostic Workup: Prognostic factor testing among older women with ductal … situ and early invasive breast cancer Breast Cancer Diagnostic Workup Data Points # 15 Prognostic factor … Current guidelines do not recommend routine testing for human epidermal growth factor receptor 2 (HER2 … Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast … ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor-2.

45. Musculoskeletal-Complaints-Tests-Children Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_executive.pdf
    March 01, 2012 - 1 Comparative Effectiveness Review Number 50 Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated … Frequency of antinuclear antibodies and rheumatoid factor in healthy Turkish children. … Rheumatoid factor in children with lupus erythematosus. A serologic study. … Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. … factor in juvenile chronic arthritis.

46. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/renal-mass-and-localized-renal-cancer-the-following-questions-are-recommended-to-address-the-healthcare-tests-andor-treatments-this-program-should-consider-what-indicators-can-be-used-to-predict-malignancy-andor-aggressivenes
    October 24, 2013 - Index or other measures) Blood and urine laboratory tests Biomarkers Pigment epithelium-derived factor … (PEDF) Vascular endothelial growth factor (VEGF) Carbonic anhydrase IX (CA-IX) KI-67 Proliferating … Hypertension is now also a well-established risk factor for renal cancer. … Studies have also identified tobacco use as a risk factor in the development of renal cancer, when compared

47. Quantitative Synthesis Chapter 3. Choice of Statistical Model for Combining Studies (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-3.pdf
    February 01, 2018 - For example, recommend against selecting fixed effects model because P>0.1 ► Such approaches do not factor … large effect sizes, or more frequent outcomes (5-10%), the Mantel-Haenszel method (without correction factor … consider the Peto method, the Mantel-Haenszel method, or logistic regression without correction factor … method, the Mantel- Haenszel method, or a logistic regression approach, without adding a correction factor

48. Topic Coming Back CER 28 DMARDs in Children with JIA NSD _SJ Clean (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_overview.pdf
    March 27, 2014 - g Categories of JIA include: • Systemic arthritis • Oligoarthritis • Rheumatoid-factor positive ( … RF+) polyarthritis • Rheumatoid-factor negative (RF-) polyarthritis • Enthesitis-related arthritis

49. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-medicine-update/final-report-update-2018
    July 16, 2018 - Two-agent treatments with MTX and tumor necrosis factor (TNF) biologics or non-TNF biologics most likely … Combination therapy with TNF (tumor necrosis factor) or non-TNF biologics plus MTX improved disease control

50. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_executive.pdf
    September 01, 2011 - Comparative Effectiveness Review Number 28 Effective Health Care 2 • Rheumatoid-factor positive … • Rheumatoid-factor negative (RF-) polyarthritis: Affects five or more joints during the first 6 months … (FDA) recently placed a box warning on the entire class of biologic DMARDs targeting tumor necrosis factor … (g) Categories of JIA include: • Systemic arthritis • Oligoarthritis • Rheumatoid-factor positive … (RF+) Polyarthritis • Rheumatoid-factor negative (RF-) polyarthritis • Enthesitis-related arthritis

51. Localized Prostate Cancer | Effective Health Care
    effectivehealthcare.ahrq.gov/decision-aids/prostate-cancer/04.html
    June 08, 2018 - Age: Age is the number one risk factor for prostate cancer.

52. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/chewing-gum-covid-19-prevention
    July 17, 2020 - Politically there is clearly a plus factor to be considered when developing a positive image for the

53. Computerized Definitions Showed High Positive Predictive Values for Identifying Reasons for Hospitalizations in a Medicaid Population with Rheumatoid Arthritis | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-hospitalizations/research
    October 30, 2008 - for post marketing studies of medication safety and we are evaluating the safety of tumor necrosis factor … and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor … Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor … Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from … opportunistic infections and other serious potential adverse events associated with tumor necrosis factor

54. Arthritis-Psoriatric Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
    April 01, 2012 - Effective Health Care infliximab) are also classified as antitumor necrosis factor (anti-TNF) drugs … component score; SF-36 = Medical Outcomes Study Short Form 36; SSZ = sulfasalazine; TNF = tumor necrosis factor … cohort studies with low strength of evidence indicated that the combination of an anti-tumor necrosis factor … Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results … Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous

55. Quantitative Synthesis: Chapter 4. Quantifying, Testing, and Exploring Statistical Heterogeneity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-4.pdf
    July 01, 2019 - meta-regression is also an option, and requires consideration of these factors as well (e.g., ≥10 studies per factor … Subgroup analysis • Subgroup analysis is a form of meta-regression with a categorical study-level factor … It is recommended to incorporate the subgroup factor into a meta-regression framework.20 − This enables … under consideration of low power associated with limited studies (i.e., <10 studies per study- level factor

56. Comparative Effectiveness of Pharmacologic Therapies for the Management of Crohn’s Disease | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/crohns-disease/research-protocol
    September 01, 2010 - antibodies, monoclonal/adverse effects”[mh] OR “anti-inflammatory agents”[mh] OR ((“tumour necrosis factor … ”[tiab] OR “tumour necrosis factor-alpha”[tiab] OR “tumor necrosis factor”[tiab] OR “tumor necrosis factor-alpha … Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for … KQ = Key question NMA = network meta-analysis RCT = randomized control trial TNF = tumor necrosis factor … for CD in children CD = Crohn’s disease; FDA = Food and Drug Administration; TNF = tumor necrosis factor

57. Observed Association Between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-seniors-pneumonia_research.pdf
    May 01, 2008 - One major etiologic factor for pneumonia in the elderly is aspiration of oropharyngeal contents [3,4 … We then examined each potential confounding factor individually using a change-in-estimate criterion … In particular, we individually added each potential confounding factor to the minimally adjusted model … If any factor changed the OR of interest by ten percent or more, we considered it to be a confounding … factor and retained it in the “change-in-estimate” adjusted model.

58. Simulation-Based Comparison of Methods for Meta-Analysis of Proportions and Rates | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/metanalysis-proportion-rate-comparison/research
    November 04, 2013 - approximate methods that require continuity corrections, as the arbitrary choice of the correction factor

59. Use of Natriuretic Peptide Measurement in the Management of Heart Failure | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/heart-failure-natriuretic-peptide/research-protocol
    December 20, 2011 - bnp1-32.mp. 6 bnp-32.mp. 7 bnp77-108.mp. 8 probnp.mp. 9 nt-probnp1-76.mp. 10 natriuretic factor … 9 bnp 77-108.tw. 10 probnp.tw. 11 nt-probnp1-76.tw. 12 nt-probnp 1-76.tw. 13 natriuretic factor … bnp 1-32.tw. 6 bnp-32.tw. 7 bnp77-108.tw. 8 probnp.tw. 9 nt-probnp1-76.tw. 10 natriuretic factor … bnp1-32.tw. 6 bnp-32.tw. 7 bnp77-108.tw. 8 probnp.tw. 9 nt-probnp1-76.tw. 10 natriuretic factor … Prognostic Factor Measurement The prognostic factor of interest is adequately measured in study

60. Disposition of Comments for Venous Thromboembolism Prophylaxis in Orthopedic Surgery (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_disposition-comments.pdf
    March 01, 2012 - I would recommend NOT using FXI as the abbreviation for Factor Xa inhbitors are there are indeed Factor … Rivaroxaban binds to factor Xa in the prothrombinase complex, clot-bound factor Xa, and free factor … Effect of BAY 59-7939–a novel, oral, direct factor Xa inhibitor–on clot- bound factor Xa activity in … Compliance for the mechanical modalities remains a factor. … Factor Xa Inhibitors, rivaroxaban and apixaban.